(Q34382099)

1 August 2017

title

Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B. (English)

1 reference

1 August 2017

1 reference

Paolo Del Poggio

1

1 reference

1 August 2017

Maurizio Zaccanelli

2

1 reference

1 August 2017

Maria Oggionni

3

1 reference

1 August 2017

Silvia Colombo

4

1 reference

1 August 2017

Carlo Jamoletti

5

1 reference

1 August 2017

Vesna Puhalo

6

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

World Journal of Gastroenterology

1 August 2017

published in

1 reference

1 August 2017

volume

13

1 reference

1 August 2017

issue

30

1 reference

1 August 2017

page(s)

4096-4099

1 reference

HIV resistance and the developing world

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Biochemical response to lamivudine treatment in HBeAg negative chronic hepatitis B patients in Iran

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Adefovir dipivoxil: review of a novel acyclic nucleoside analogue

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Tenofovir disoproxil fumarate: role in hepatitis B treatment

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Reactivation of viral replication after replacement of tenofovir by adefovir

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205311

27 October 2018

Identifiers

DOI

10.3748/WJG.V13.I30.4096

1 reference

1 August 2017

1 reference

1 August 2017

1 reference